Product Description
For Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01710644)
Mechanisms of Action: LIP Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nordmark Arzneimittel
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Intestinal Diseases|Exocrine Pancreatic Insufficiency|Cystic Fibrosis|Pancreatic Cyst|Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NM-BL-101 | P2 |
Completed |
Intestinal Diseases|Pancreatic Cyst|Cystic Fibrosis|Exocrine Pancreatic Insufficiency|Respiratory Insufficiency |
2014-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|